SOW
ACRS icon

State of Wyoming’s Aclaris Therapeutics ACRS Stock Holding History

State of Wyoming’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-46,861
Closed -$71.7K – 1836
2025
Q1 		$71.7K Buy
+46,861
New +$100K 0.01% 1314
2023
Q1 		– Sell
-5,533
Closed -$87.1K – 1572
2022
Q4 		$87.1K Buy
+5,533
New +$89K 0.03% 841

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State of Wyoming's ACRS Position: Q2 2025 in Review

State of Wyoming sold out of Aclaris Therapeutics (ACRS) in Q2 2025, closing a stake of 46,861 shares — an estimated $71.7K sold.

State of Wyoming first reported a position in ACRS in Q4 2022 and held it in 2 quarters. The position peaked at $87.1K in Q4 2022. 96 funds tracked by Wall St. Rank hold ACRS as of Q2 2025.

  • State of Wyoming reported no remaining Aclaris Therapeutics position as of Q2 2025 after selling out during the quarter.
  • State of Wyoming sold 46,861 Aclaris Therapeutics shares in Q2 2025, an estimated $71.7K.
  • State of Wyoming first reported a position in Aclaris Therapeutics in Q4 2022 and held it in 2 quarters.
  • State of Wyoming's Aclaris Therapeutics position peaked at $87.1K in Q4 2022.
  • 96 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2025.

Based on State of Wyoming's 13F filing for Q2 2025, filed 19 Aug 2025.